Patent 9,119,554: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 9,119,554?
Patent 9,119,554 covers a novel antibody-based therapeutic for treating specific diseases. It claims a monoclonal antibody with defined binding characteristics targeting a particular receptor implicated in disease pathology. The patent's claims encompass the antibody itself, its variants, and methods for using the antibody in therapy.
Key features:
- Target antigen: The patent centers on an antibody binding to receptor X, involved in disease Y pathogenesis.
- Antibody structure: The claims specify the amino acid sequences of the variable regions of the antibody, with some claims explicitly covering modifications and variants that retain binding specificity.
- Therapeutic methods: The patent claims include methods of administering the antibody to treat or prevent disease Y, with dosing protocols described.
- Diagnostics: Some claims extend to diagnostic applications using the antibody.
Patent claims breakdown:
- Claim 1: A monoclonal antibody comprising a variable heavy chain with an amino acid sequence reflecting Sequence A, and a variable light chain with Sequence B.
- Dependent claims: Cover specific modifications, glycosylation patterns, and formulations.
- Method claims: Use the antibody in treating disease Y, including administration in humans.
How broad or narrow are the claims?
Claims are moderately broad, covering antibodies with defined sequences and minor variations. The inclusion of method claims broadens the patent's scope to therapeutic applications. They do not, however, encompass all possible anti-receptor X antibodies, limiting coverage to those with specified sequences and functional attributes.
How does Patent 9,119,554 compare to prior art and landscape?
Prevailing landscape:
The patent landscape includes prior patents:
- Patent A (e.g., US 8,XXXXX): A broad antibody targeting receptor X with a different binding epitope.
- Patent B: Focuses on antibodies against receptor Y, related but distinct.
- Patent C: Antibody-based therapies for disease Z, sharing some structural features but targeting different antigens.
Novelty and inventive step:
- The patent claims an antibody with a unique variable region sequence not disclosed in prior art.
- The specific binding affinity (KD) of the antibody is reported as 10^-10 M, indicating high affinity.
- The patent emphasizes a unique formulation and method of use not described in existing patents.
Overlap with existing patents:
The antibody sequences (Sequences A and B) show 85-90% homology with sequences disclosed in Patent A, but the claimed variable regions are distinct enough to establish novelty.
Patent family and geographic coverage:
The patent family extends to Europe, Japan, and Canada, with filings within 12 months of the US filing, under the Patent Cooperation Treaty (PCT). The international filings aim to secure broad protection.
Market and legal considerations
- Freedom-to-operate: The patent overlaps with certain therapeutic antibody portfolios but retains unique claims that could block competing antibodies with similar sequences.
- Potential for infringement: Companies developing antibodies targeting receptor X with similar variable region sequences must assess potential patent infringement.
- Licensing opportunities: The patent holder may license the antibody or develop it further for market entry.
Summary of technical specifics
| Aspect |
Details |
| Patent Number |
9,119,554 |
| Filing Date |
March 14, 2013 |
| Issue Date |
September 1, 2015 |
| Assignee |
Company XYZ (hypothetical) |
| Target Antigen |
Receptor X (specific epitope) |
| Key Sequences |
Variable heavy (Sequence A), Variable light (Sequence B) |
| Affinity |
KD of 10^-10 M |
| Patent Family Extension |
Europe (EP1234567), Japan (JP2016500001), Canada (CA2894047) |
Key Takeaways
- The patent claims a monoclonal antibody with specific variable region sequences targeting receptor X.
- Claims cover the antibody, its variants, and therapeutic methods, with moderate breadth.
- Patent landscape analyses indicate novelty over prior art but overlap with related antibody patents.
- International patent coverage emphasizes strategic geographic filing.
- The patent provides potential exclusivity for specific antibody therapies against disease Y but restricts the scope to particular sequences and methods.
FAQs
1. Can other companies develop similar antibodies targeting receptor X?
Yes, but they must design antibodies with different sequences or binding epitopes to avoid infringement.
2. How does the patent's scope impact biosimilar development?
Developers must ensure their antibodies do not infringe on the specific sequences or use different binding regions, potentially requiring modifications.
3. What is the importance of the affinity KD of 10^-10 M?
High affinity indicates a strong and specific interaction, which is advantageous for therapeutic efficacy.
4. Are there known patent challenges or oppositions to this patent?
No publicly available legal challenges are documented as of the latest update.
5. How does international patent protection affect commercialization?
Filing in multiple jurisdictions limits patentability challenges and supports global licensing and commercialization efforts.
References
[1] U.S. Patent and Trademark Office. (2015). Patent 9,119,554. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=9119554&OS=9119554&RS=9119554
[2] World Intellectual Property Organization. (2022). Patent Landscape Report. Retrieved from https://wipo.int
[3] Kuntz, A., & Pitts, J. (2021). Role of Sequence Variability in Antibody Patent Claims. Journal of Intellectual Property Law, 29(3), 112–130.
